Stockscreener 앱 받기
230.18
1.38%
-3.21
시간 외 거래:
230.18
전일 마감가:
$233.39
열려 있는:
$233.43
하루 거래량:
349.62K
Relative Volume:
0.69
시가총액:
$8.91B
수익:
$1.24B
순이익/손실:
$42.23M
주가수익비율:
217.15
EPS:
1.06
순현금흐름:
$150.33M
1주 성능:
+0.03%
1개월 성능:
-9.99%
6개월 성능:
-16.01%
1년 성능:
+19.13%
1일 변동 폭
$229.13
$235.40
1주일 범위
$226.66
$235.40
52주 변동 폭
$148.00
$310.00
Penumbra Inc Stock (PEN) Company Profile
명칭
Penumbra Inc
전화
(510) 995-2486
주소
ONE PENUMBRA PLACE, ALAMEDA, CA
PEN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PEN
Penumbra Inc
|
230.18 | 9.04B | 1.24B | 42.23M | 150.33M | 1.06 |
|
ABT
Abbott Laboratories
|
125.64 | 218.92B | 43.11B | 13.98B | 6.66B | 7.98 |
|
BSX
Boston Scientific Corp
|
106.21 | 152.62B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
396.66 | 153.22B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
92.32 | 117.89B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
75.80 | 45.12B | 5.54B | 4.18B | 623.10M | 7.00 |
Penumbra Inc Stock (PEN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-14 | 개시 | BofA Securities | Buy |
| 2025-01-21 | 개시 | UBS | Buy |
| 2024-12-17 | 개시 | Oppenheimer | Outperform |
| 2024-12-11 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-09-18 | 개시 | Stifel | Buy |
| 2024-09-03 | 개시 | Leerink Partners | Outperform |
| 2024-07-31 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-07-31 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-02-23 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2023-09-06 | 개시 | Morgan Stanley | Equal-Weight |
| 2023-07-19 | 개시 | Robert W. Baird | Outperform |
| 2023-03-29 | 다운그레이드 | Needham | Buy → Hold |
| 2023-01-30 | 개시 | Piper Sandler | Overweight |
| 2022-11-04 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-10-12 | 개시 | Jefferies | Buy |
| 2022-10-05 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-09-09 | 업그레이드 | Needham | Hold → Buy |
| 2022-07-18 | 개시 | RBC Capital Mkts | Outperform |
| 2022-04-19 | 개시 | Deutsche Bank | Buy |
| 2022-03-08 | 개시 | Needham | Hold |
| 2021-09-16 | 개시 | Truist | Buy |
| 2021-06-04 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2020-12-16 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2020-10-07 | 재개 | Canaccord Genuity | Buy |
| 2020-09-29 | 개시 | BTIG Research | Buy |
| 2020-09-08 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2019-06-13 | 재확인 | BofA/Merrill | Buy |
| 2019-05-30 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-05-21 | 개시 | William Blair | Outperform |
| 2018-10-29 | 재개 | BofA/Merrill | Buy |
| 2018-10-08 | 개시 | RBC Capital Mkts | Outperform |
| 2018-02-21 | 개시 | William Blair | Outperform |
| 2018-01-02 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2015-11-30 | 재확인 | Canaccord Genuity | Buy |
| 2015-10-13 | 개시 | Wells Fargo | Outperform |
모두보기
Penumbra Inc 주식(PEN)의 최신 뉴스
Will Penumbra (PEN) Beat Estimates Again in Its Next Earnings Report? - Yahoo.co
Penumbra Inc. Stock Analysis and ForecastExtraordinary performance - Autocar Professional
Is Penumbra Inc. a good long term investmentFree Stock Chart Pattern Guide - jammulinksnews.com
What analysts say about Penumbra Inc. stockExplosive capital gains - jammulinksnews.com
Penumbra (PEN) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
What drives Penumbra Inc. stock priceFree Popular Stock Recommendations - jammulinksnews.com
Penumbra, Inc. Schedules Second Quarter 2025 Earnings Release and Conference Call for July 29, 2025 - Eastern Progress
Penumbra, Inc.'s (NYSE:PEN) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock? - simplywall.st
Penumbra's Strategic Growth Potential Bolstered by Upcoming Thunderbolt System Launch and Aspiration Technology Innovation - AInvest
Penumbra CEO's Stock Sale: A Routine Maneuver or Cause for Concern? - AInvest
Penumbra Insider Sold Shares Worth $3,896,344, According to a Recent SEC Filing - MarketScreener
Penumbra CEO Elsesser sells $3.89m in shares By Investing.com - Investing.com Nigeria
Penumbra CEO Elsesser sells $3.89m in shares - Investing.com Australia
NeoGenomics, RadNet, Pediatrix Medical Group, Penumbra, and Neogen Shares Plummet, What You Need To Know - Yahoo Finance
Penumbra (PEN) Announces Completion of Enrollment in STORM-PE Clinical Trial - Insider Monkey
Penumbra (PEN) Sees Price Target Reduction by Citi Ahead of Earnings | PEN Stock News - GuruFocus
11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds - Insider Monkey
Penumbra, Inc.'s (NYSE:PEN) P/S Still Appears To Be Reasonable - 富途牛牛
Insider Sell: Johanna Roberts Sells 600 Shares of Penumbra Inc (PEN) - GuruFocus
Penumbra EVP Roberts sells $151k in company stock By Investing.com - Investing.com Canada
Penumbra EVP Roberts sells $151k in company stock - Investing.com
Penumbra Inc EVP Sells 571 Shares for $144,143.47 on July 1, 2025. - AInvest
Penumbra CEO Adam Elsesser sells $4m in stock on June 25 - Investing.com Nigeria
Penumbra: AI Meets AspirationWhy The Stock Is A Structural Winner - Seeking Alpha
Thrombectomy Devices Market | Advancing Stroke Treatment & Clot - openPR.com
Penumbra may gain market share in peripheral embolisation coils with Ruby XL - Yahoo Finance
Insider Selling: Bridget O'Rourke Sells Shares of Penumbra Inc (PEN) - GuruFocus
Penumbra director O’Rourke sells $12988 in stock - Investing.com
Inquis, Penumbra advance thrombectomy treatments - BioWorld MedTech
Transcript : Penumbra, Inc. Presents at 2025 Truist Securities MedTech Conference, Jun-17-2025 10 - MarketScreener
Penumbra, Inc. Announces Completion of Enrollment for Landmark S - GuruFocus
Penumbra Completes Enrollment for STORM-PE Randomized Controlled Trial - Diagnostic and Interventional Cardiology
Penumbra completes enrollment in pulmonary embolism trial - MassDevice
Penumbra's Revolutionary PE Treatment Trial Hits 100-Patient Mark, Results Could Transform Blood Clot Care - Stock Titan
Clot Management Devices Market Set to Witness Significant - openPR.com
PEN Stock Rises Following the Launch of Ruby XL System - MSN
Penumbra Inc (PEN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.03%
0.79%
자본화:
|
볼륨(24시간):